Granted Patent
B2
US 12,391,957 · App. 17/268,403 · Granted Aug 19, 2025
Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
Inventors:
Joan E. Durbin (Sergeantsville, NJ); Russell K. Durbin (Sergeantsville, NJ); Adolfo Garcia-Sastre (New York, NY); Ignacio Mena (New York, NY); Peter Palese (New York, NY)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a respiratory syncytial virus (“RSV”) F protein or human metapneumovirus (“hMPV”) F protein. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises (i) an RSV F protein ectodomain and NDV F protein transmembrane and cytoplasmic domains; or (ii) an hMPV F protein ectodomain and NDV F protein transmembrane and cytoplasmic domains. The recombinant NDVs and compositions thereof are useful for the immunizing against RSV or hMPV as well as the prevention of RSV disease or hMPV disease.
Claims (29)
1. A recombinant Newcastle disease virus (NDV) comprising a packaged genome comprising
(a) a transgene encoding a fusion (F) protein of a human virus of the family Pneumoviridae, wherein the transgene comprises
(i) a ribonucleic acid (RNA) sequence corresponding to the negative sense of the complementary deoxyribonucleic acid (cDNA) sequence of SEQ ID NO: 2, 26, 28, or 30, or
(ii) an RNA sequence corresponding to the negative sense of the cDNA sequence of SEQ ID NO: 18, 53, 55, or 57;
(b) a transgene encoding a chimeric protein comprising an ectodomain of a F protein of a human virus of the family Pneumoviridae and a transmembrane domain and a cytoplasmic domain of a NDV F protein, wherein:
(i) the human virus of the family Pneumoviridae is human respiratory syncytial virus (“RSV”), and the chimeric protein comprises the ectodomain of the amino acid sequence set forth in SEQ ID NO:7,
(ii) the transgene comprises an RNA sequence corresponding to the negative sense of the cDNA sequence of SEQ ID NO: 19, 32, 34, 35, or 36, or
(iii) the transgene comprises an RNA sequence corresponding to the negative sense of the cDNA sequence of SEQ ID NO: 4, 44, 45, or 46; or
(c) a transgene encoding a bovine respiratory syncytial virus (“RSV”) F protein, wherein the transgene comprises an RNA sequence corresponding to the negative sense of the cDNA sequence of SEQ ID NO: 11, 41, or 43; or
(d) a transgene encoding a chimeric protein comprising a bovine Respiratory Syncytial Virus (RSV) F protein ectodomain and a transmembrane domain and a cytoplasmic domain of a NDV F protein, wherein:
(i) the chimeric protein comprises the amino acid sequence set forth in SEQ ID NO:33, or
(ii) the transgene comprises an RNA sequence corresponding to the negative sense of the cDNA sequence of SEQ ID NO: 14, 31, 38, or 39.
2. The recombinant NDV of claim 1 , wherein the human virus of the family Pneumoviridae is the RSV, and the chimeric protein comprises the ectodomain of the amino acid sequence set forth in SEQ ID NO:7.
3. The recombinant NDV of claim 1 , wherein the genome comprises a negative sense RNA sequence transcribed from the cDNA sequence set forth in SEQ ID NO: 3, 5, 13, 37 or 59.
4. An immunogenic composition comprising the recombinant NDV of claim 1 .
5. A method for inducing an immune response to an F protein of a human virus of the family Pneumoviridae in a subject, preventing a human virus of the family Pneumoviridae disease in a subject, or immunizing a subject against a human virus of the family Pneumoviridae, comprising administering the immunogenic composition of claim 4 to the subject.
6. The recombinant NDV of claim 1 , wherein the chimeric protein comprises the amino acid sequence set forth in SEQ ID NO:33.
7. The recombinant NDV of claim 1 , wherein the transgene comprises an RNA sequence corresponding to the negative sense of the cDNA sequence of SEQ ID NO: 11, 14, 31, 38, 39, 41, or 43.
8. A method for inducing an immune response to RSV F protein to a bovine subject, preventing an RSV disease in a bovine subject, or immunizing a bovine subject against RSV, the method comprising administering the immunogenic composition of claim 1 to the bovine subject.
9. A method for inducing an immune response to RSV F protein in a human subject seropositive for anti-RSV F antibodies, preventing an RSV disease in a human subject seropositive for anti-RSV F antibodies, or immunizing a subject against RSV in a human subject seropositive for anti-RSV F antibodies, the method comprising administering the immunogenic composition of claim 1 to the human subject.
10. The recombinant NDV of claim 1 , wherein (a) the F protein of a human virus of the family Pneumoviridae is a human metapneumovirus (“hMPV”) F protein; or (b) the ectodomain of a fusion (F) protein of a human virus of the family Pneumoviridae is a human metapneumovirus (hMPV) fusion (F) protein ectodomain.
11. The recombinant NDV of claim 10 , wherein the transgene comprises an RNA sequence corresponding to the negative sense of the cDNA sequence of SEQ ID NO: 18, 53, 55, 57, 19, 32, 34, 35 or 36.
12. The recombinant NDV of claim 10 , wherein the genome comprises a negative sense RNA sequence transcribed from the cDNA sequence set forth in SEQ ID NO: 21, or 22.
13. An immunogenic composition comprising the recombinant NDV of claim 10 .
14. A method for inducing an immune response to hMPV F protein, preventing an hMPV disease, or immunizing a subject against hMPV, the method comprising administering the immunogenic composition of claim 13 to a human subject.
15. A cell line or chicken embryonated egg comprising the propagating the recombinant NDV of claim 1 .
16. A method for propagating the recombinant NDV of claim 1 , the method comprising culturing the cell or embryonated egg of claim 15 .
17. The recombinant NDV of claim 1 , wherein the transgene comprises an RNA sequence corresponding to the negative sense of the cDNA sequence of SEQ ID NO: 2, 26, 28, or 30.
18. The recombinant NDV of claim 1 , wherein the transgene comprises an RNA sequence corresponding to the negative sense of the cDNA sequence of SEQ ID NO: 4, 44, 45, or 46.
Assignments (3)
CONFIRMATORY LICENSE
Recorded Nov 22, 2023
From: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065664/0432 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 24, 2021
From: DURBIN, JOAN E.; DURBIN, RUSSELL K.
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 058207/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 24, 2021
From: GARCIA-SASTRE, ADOLFO; MENA, IGNACIO; PALESE, PETER
To: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Reel/Frame 058207/0516 →
Continuity (2)
Provisional Application
62765242
· Aug 17, 2018
References Cited (400)
US 4444887A
· Hoffman
· 1984
[cited by applicant]
US 4474893A
· Reading
· 1984
[cited by applicant]
US 4676980A
· Segal et al.
· 1987
[cited by applicant]
US 4714681A
· Reading
· 1987
[cited by applicant]
US 4716111A
· Osband et al.
· 1987
[cited by applicant]
US 4816397A
· Boss et al.
· 1989
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4925648A
· Hansen et al.
· 1990
[cited by applicant]
US 5122464A
· Wilson et al.
· 1992
[cited by applicant]
US 5166057A
· Palese et al.
· 1992
[cited by applicant]
US 5223409A
· Ladner et al.
· 1993
[cited by applicant]
US 5225539A
· Winter
· 1993
[cited by applicant]
US 5273745A
· Schirrmacher
· 1993
[cited by applicant]
US 5403484A
· Ladner et al.
· 1995
[cited by applicant]
US 5413923A
· Kucherlapati et al.
· 1995
[cited by applicant]
US 5427908A
· Dower et al.
· 1995
[cited by applicant]
US 5516637A
· Huang et al.
· 1996
[cited by applicant]
US 5530101A
· Queen et al.
· 1996
[cited by applicant]
US 5545806A
· Lonberg et al.
· 1996
[cited by applicant]
US 5565332A
· Hoogenboom et al.
· 1996
[cited by applicant]
US 5569825A
· Lonberg et al.
· 1996
[cited by applicant]
US 5571698A
· Ladner et al.
· 1996
[cited by applicant]
US 5573920A
· Randle
· 1996
[cited by applicant]
US 5580717A
· Dower et al.
· 1996
[cited by applicant]
US 5585089A
· Queen et al.
· 1996
[cited by applicant]
US 5601819A
· Wong et al.
· 1997
[cited by applicant]
US 5625126A
· Lonberg et al.
· 1997
[cited by applicant]
US 5633425A
· Lonberg et al.
· 1997
[cited by applicant]
US 5658727A
· Barbas et al.
· 1997
[cited by applicant]
US 5661016A
· Lonberg et al.
· 1997
[cited by applicant]
US 5698426A
· Huse
· 1997
[cited by applicant]
US 5731168A
· Carter et al.
· 1998
[cited by applicant]
US 5733743A
· Stuart et al.
· 1998
[cited by applicant]
US 5750753A
· Kimae et al.
· 1998
[cited by applicant]
US 5766886A
· Studnicka et al.
· 1998
[cited by applicant]
US 5780225A
· Wigler et al.
· 1998
[cited by applicant]
US 5786199A
· Palese
· 1998
[cited by applicant]
US 5807715A
· Morrison et al.
· 1998
[cited by applicant]
US 5814318A
· Lonberg et al.
· 1998
[cited by applicant]
US 5820871A
· Palese et al.
· 1998
[cited by applicant]
US 5821047A
· Garrard et al.
· 1998
[cited by applicant]
US 5854037A
· Palese et al.
· 1998
[cited by applicant]
US 5891680A
· Lieschke et al.
· 1999
[cited by applicant]
US 5939598A
· Kucherlapati et al.
· 1999
[cited by applicant]
US 5969108A
· McCafferty et al.
· 1999
[cited by applicant]
US 6005079A
· Casterman et al.
· 1999
[cited by applicant]
US 6146642A
· Garcia-Sastre et al.
· 2000
[cited by applicant]
US 6190901B1
· Sundick et al.
· 2001
[cited by applicant]
US 6287554B1
· Sundick et al.
· 2001
[cited by applicant]
US 6329511B1
· Vasquez et al.
· 2001
[cited by applicant]
US 6331415B1
· Cabilly et al.
· 2001
[cited by applicant]
US 6407213B1
· Carter et al.
· 2002
[cited by applicant]
US 6451323B1
· Garcia-Sastre et al.
· 2002
[cited by applicant]
US 6544785B1
· Palese et al.
· 2003
[cited by applicant]
US 6635416B2
· Palese et al.
· 2003
[cited by applicant]
US 6649372B1
· Palese et al.
· 2003
[cited by applicant]
US 6669943B1
· Palese et al.
· 2003
[cited by applicant]
US 6719979B2
· Peeters et al.
· 2004
[cited by applicant]
US 6737522B2
· Sundick et al.
· 2004
[cited by applicant]
US 6811784B2
· Haller et al.
· 2004
[cited by applicant]
US 6852522B1
· Palese et al.
· 2005
[cited by applicant]
US 6896881B1
· Russell et al.
· 2005
[cited by applicant]
US 7052685B1
· Rook
· 2006
[cited by applicant]
US 7056689B1
· Lorence et al.
· 2006
[cited by applicant]
US 7060430B2
· Palese et al.
· 2006
[cited by applicant]
US 7141550B2
· Molling et al.
· 2006
[cited by applicant]
US 7223389B2
· Zakay-Rones et al.
· 2007
[cited by applicant]
US 7244558B1
· Samal et al.
· 2007
[cited by applicant]
US 7332169B2
· Peeters et al.
· 2008
[cited by applicant]
US 7384774B2
· Palese et al.
· 2008
[cited by applicant]
US 7442379B2
· Garcia-sastre et al.
· 2008
[cited by applicant]
US 7442527B2
· Palese et al.
· 2008
[cited by applicant]
US 7470426B1
· Roberts et al.
· 2008
[cited by applicant]
US 7488802B2
· Collins et al.
· 2009
[cited by applicant]
US 7494808B2
· Palese et al.
· 2009
[cited by applicant]
US 7547442B2
· Peeters et al.
· 2009
[cited by applicant]
US 7709226B2
· Foote
· 2010
[cited by applicant]
US 7736640B2
· Lorence et al.
· 2010
[cited by applicant]
US 7780962B2
· Roberts et al.
· 2010
[cited by applicant]
US 7833774B2
· Palese et al.
· 2010
[cited by applicant]
US 7858081B2
· Bernard et al.
· 2010
[cited by applicant]
US 8043612B2
· Roberts et al.
· 2011
[cited by applicant]
US 8105578B2
· Roberts et al.
· 2012
[cited by applicant]
US 8124084B2
· Lefrancois et al.
· 2012
[cited by applicant]
US 8163879B2
· Wong et al.
· 2012
[cited by applicant]
US 8168757B2
· Finnefrock et al.
· 2012
[cited by applicant]
US 8326547B2
· Liu et al.
· 2012
[cited by applicant]
US 8354509B2
· Craven et al.
· 2013
[cited by applicant]
US 8475790B2
· Jure-Kunkel
· 2013
[cited by applicant]
US 8486418B2
· Bublot et al.
· 2013
[cited by applicant]
US 8490289B2
· Nystrom et al.
· 2013
[cited by applicant]
US 8492118B2
· Wong et al.
· 2013
[cited by applicant]
US 8507222B2
· Wong et al.
· 2013
[cited by applicant]
US 8591881B2
· Palese et al.
· 2013
[cited by applicant]
US 8709417B2
· Allison et al.
· 2014
[cited by applicant]
US 8765462B2
· Medin et al.
· 2014
[cited by applicant]
US 8871191B2
· Pavlakis et al.
· 2014
[cited by applicant]
US 8900587B2
· Craven et al.
· 2014
[cited by applicant]
US 8940288B2
· Lefrancois et al.
· 2015
[cited by applicant]
US 8952136B2
· Carven et al.
· 2015
[cited by applicant]
US 9217136B2
· Palese et al.
· 2015
[cited by applicant]
US 9370563B2
· Morales et al.
· 2016
[cited by applicant]
US 9375475B2
· Allison et al.
· 2016
[cited by applicant]
US 9387242B2
· Palese et al.
· 2016
[cited by applicant]
US 9476033B2
· Samal et al.
· 2016
[cited by applicant]
US 9616118B2
· Bublot et al.
· 2017
[cited by applicant]
US 9642298B1
· Martin
· 2017
[cited by applicant]
US 9821016B2
· Lauer et al.
· 2017
[cited by applicant]
US 9937196B2
· Samal et al.
· 2018
[cited by applicant]
US 20020052030A1
· Wonderling et al.
· 2002
[cited by applicant]
US 20020150554A1
· Sundick et al.
· 2002
[cited by applicant]
US 20030044384A1
· Roberts et al.
· 2003
[cited by applicant]
US 20030224017A1
· Samal et al.
· 2003
[cited by applicant]
US 20040005545A1
· Fouchier et al.
· 2004
[cited by applicant]
US 20050042664A1
· Wu et al.
· 2005
[cited by applicant]
US 20050191617A1
· Inoue et al.
· 2005
[cited by applicant]
US 20050238622A1
· Axelrod et al.
· 2005
[cited by applicant]
US 20060159695A1
· Delvecchio et al.
· 2006
[cited by applicant]
US 20080206201A1
· Beier et al.
· 2008
[cited by applicant]
US 20090061521A1
· Palese et al.
· 2009
[cited by applicant]
US 20090175826A1
· Subbiah et al.
· 2009
[cited by applicant]
US 20090214590A1
· Sundick et al.
· 2009
[cited by applicant]
US 20090280144A1
· Garcia-sastre et al.
· 2009
[cited by applicant]
US 20100092430A1
· Beier et al.
· 2010
[cited by applicant]
US 20100297072A1
· DePinho et al.
· 2010
[cited by applicant]
US 20110020282A1
· Beier et al.
· 2011
[cited by applicant]
US 20110044937A1
· Bell et al.
· 2011
[cited by applicant]
US 20120034242A1
· Jooss et al.
· 2012
[cited by applicant]
US 20120058538A1
· Palese et al.
· 2012
[cited by applicant]
US 20130084264A1
· Schrier et al.
· 2013
[cited by applicant]
US 20130108665A1
· Liang
· 2013
[cited by applicant]
US 20140159960A1
· Mueller
· 2014
[cited by applicant]
US 20140271677A1
· Palese et al.
· 2014
[cited by applicant]
US 20150017121A1
· Becher et al.
· 2015
[cited by applicant]
US 20150133531A1
· Wiegand
· 2015
[cited by applicant]
US 20150152188A1
· Morisseau et al.
· 2015
[cited by applicant]
US 20150250837A1
· Nolin et al.
· 2015
[cited by applicant]
US 20160015760A1
· Palese et al.
· 2016
[cited by applicant]
US 20180078592A1
· Palese et al.
· 2018
[cited by applicant]
US 20180256655A1
· Palese et al.
· 2018
[cited by applicant]
AU 2002307971B2
· 2008
[cited by applicant]
CN 101787373A
· 2010
[cited by applicant]
CN 102740887A
· 2012
[cited by applicant]
CN 105734023A
· 2016
[cited by applicant]
CN 106166294A
· 2016
[cited by applicant]
DE 3922444A1
· 1991
[cited by applicant]
EP 0239400B1
· 1994
[cited by applicant]
EP 0702085A1
· 1996
[cited by applicant]
EP 0780475B1
· 1997
[cited by applicant]
EP 0974660A1
· 2000
[cited by applicant]
EP 0592106B1
· 2004
[cited by applicant]
EP 0519596B1
· 2005
[cited by applicant]
EP 1248654B1
· 2005
[cited by applicant]
EP 1032269B1
· 2007
[cited by applicant]
EP 1486211B1
· 2008
[cited by applicant]
EP 2085092A1
· 2009
[cited by applicant]
EP 0702085B2
· 2010
[cited by applicant]
EP 2669381A1
· 2013
[cited by applicant]
EP 2579884B1
· 2014
[cited by applicant]
EP 2393921B1
· 2015
[cited by applicant]
EP 2987856A1
· 2016
[cited by applicant]
EP 2766035B1
· 2018
[cited by applicant]
JP 2012527465A
· 2012
[cited by applicant]
WO WO1986005807A1
· 1986
[cited by applicant]
WO WO1989001036A1
· 1989
[cited by applicant]
WO WO1990002809A1
· 1990
[cited by applicant]
WO WO1991000360A1
· 1991
[cited by applicant]
WO WO1991009967A1
· 1991
[cited by applicant]
WO WO1991010737A1
· 1991
[cited by applicant]
WO WO1991010741A1
· 1991
[cited by applicant]
WO WO1992000373A1
· 1992
[cited by applicant]
WO WO1992001047A1
· 1992
[cited by applicant]
WO WO1992008802A1
· 1992
[cited by applicant]
WO WO1992018619A1
· 1992
[cited by applicant]
WO WO1992022324A1
· 1992
[cited by applicant]
WO WO1993011236A1
· 1993
[cited by applicant]
WO WO1993017105A1
· 1993
[cited by applicant]
WO WO1993017715A1
· 1993
[cited by applicant]
WO WO1994004678A1
· 1994
[cited by applicant]
WO WO1994004690A1
· 1994
[cited by applicant]
WO WO1994025591A1
· 1994
[cited by applicant]
WO WO1994025627A1
· 1994
[cited by applicant]
WO WO1995015982A2
· 1995
[cited by applicant]
WO WO1995015982A3
· 1995
[cited by applicant]
WO WO1995020401A1
· 1995
[cited by applicant]
WO WO1996033735A1
· 1996
[cited by applicant]
WO WO1996034096A1
· 1996
[cited by applicant]
WO WO1996034625A1
· 1996
[cited by applicant]
WO WO1997006270A1
· 1997
[cited by applicant]
WO WO1997012032A1
· 1997
[cited by applicant]
WO WO1997013844A1
· 1997
[cited by applicant]
WO WO1997014433A1
· 1997
[cited by applicant]
WO WO1998002530A1
· 1998
[cited by applicant]
WO WO1998013501A2
· 1998
[cited by applicant]
WO WO1998013501A3
· 1998
[cited by applicant]
WO WO1998016654A1
· 1998
[cited by applicant]
WO WO1998024893A2
· 1998
[cited by applicant]
WO WO1998024893A3
· 1998
[cited by applicant]
WO WO1998046645A2
· 1998
[cited by applicant]
WO WO1998046645A3
· 1998
[cited by applicant]
WO WO1998050433A2
· 1998
[cited by applicant]
WO WO1998050433A3
· 1998
[cited by applicant]
WO WO1998053078A1
· 1998
[cited by applicant]
WO WO1999002657A1
· 1999
[cited by applicant]
WO WO1999015672A1
· 1999
[cited by applicant]
WO WO1999018799A1
· 1999
[cited by applicant]
WO WO1999066045A1
· 1999
[cited by applicant]
WO WO2000062735A2
· 2000
[cited by applicant]
WO WO2000062735A3
· 2000
[cited by applicant]
WO WO2000067786A1
· 2000
[cited by applicant]
WO WO2001004333A1
· 2001
[cited by applicant]
WO WO2001020989A1
· 2001
[cited by applicant]
WO WO2001044301A1
· 2001
[cited by applicant]
WO WO2002081621A2
· 2002
[cited by applicant]
WO WO2002081621A3
· 2002
[cited by applicant]
WO WO2002102404A1
· 2002
[cited by applicant]
WO WO2003092579A2
· 2003
[cited by applicant]
WO WO2003092579A3
· 2003
[cited by applicant]
WO WO2006042156
· 2006
[cited by examiner]
WO WO2006050984A2
· 2006
[cited by applicant]
WO WO2006050984A3
· 2006
[cited by applicant]
WO WO2007001677A2
· 2007
[cited by applicant]
WO WO2007001677A3
· 2007
[cited by applicant]
WO WO2007008918A2
· 2007
[cited by applicant]
WO WO2007008918A3
· 2007
[cited by applicant]
WO WO2007064802A1
· 2007
[cited by applicant]
WO WO2007084342A2
· 2007
[cited by applicant]
WO WO2007084342A3
· 2007
[cited by applicant]
WO WO2007113648A2
· 2007
[cited by applicant]
WO WO2007113648A3
· 2007
[cited by applicant]
WO WO2008011726A1
· 2008
[cited by applicant]
WO WO2008156712A1
· 2008
[cited by applicant]
WO WO2009002562A2
· 2008
[cited by applicant]
WO WO2009002562A3
· 2008
[cited by applicant]
WO WO2009095167A1
· 2009
[cited by applicant]
WO WO2009101149A2
· 2009
[cited by applicant]
WO WO2009101149A3
· 2009
[cited by applicant]
WO WO2010091262A1
· 2010
[cited by applicant]
WO WO2010135242A1
· 2010
[cited by applicant]
WO WO2011022656A2
· 2011
[cited by applicant]
WO WO2011022656A3
· 2011
[cited by applicant]
WO WO2011041613A2
· 2011
[cited by applicant]
WO WO2011041613A3
· 2011
[cited by applicant]
WO WO2011119628A2
· 2011
[cited by applicant]
WO WO2011119628A3
· 2011
[cited by applicant]
WO WO2011154476A1
· 2011
[cited by applicant]
WO WO2012000188A1
· 2012
[cited by applicant]
WO WO2012000443A1
· 2012
[cited by applicant]
WO WO2012142529A2
· 2012
[cited by applicant]
WO WO2012142529A3
· 2012
[cited by applicant]
WO WO2013053775A1
· 2013
[cited by applicant]
WO WO2013112942A1
· 2013
[cited by applicant]
WO WO2013178344A1
· 2013
[cited by applicant]
WO WO2014047350A1
· 2014
[cited by applicant]
WO WO2014066527A2
· 2014
[cited by applicant]
WO WO2014066527A3
· 2014
[cited by applicant]
WO WO2014158811A1
· 2014
[cited by applicant]
WO WO2014170032A1
· 2014
[cited by applicant]
WO WO2015018528A1
· 2015
[cited by applicant]
WO WO2015018529A1
· 2015
[cited by applicant]
WO WO2015032755A1
· 2015
[cited by applicant]
WO WO2015127501A1
· 2015
[cited by applicant]
WO WO2015131994A1
· 2015
[cited by applicant]
WO WO2016018920A1
· 2016
[cited by applicant]
WO WO2016048903A1
· 2016
[cited by applicant]
WO WO2016094377A1
· 2016
[cited by applicant]
WO WO2017019894A1
· 2017
[cited by applicant]
WO WO2017019896A1
· 2017
[cited by applicant]
WO WO2017019897A1
· 2017
[cited by applicant]
WO WO2017062953A1
· 2017
[cited by applicant]
WO WO2017083291A1
· 2017
[cited by applicant]
WO WO2017118867A1
· 2017
[cited by applicant]
WO WO2017123981A1
· 2017
[cited by applicant]
WO WO2017190112A1
· 2017
[cited by applicant]
WO WO2018027316A1
· 2018
[cited by applicant]
WO WO2018209194A2
· 2018
[cited by applicant]
WO WO2018209194A3
· 2018
[cited by applicant]
WO WO2018218151A1
· 2018
[cited by applicant]
WO WO2019197275A1
· 2019
[cited by applicant]
WO WO2019209859A1
· 2019
[cited by applicant]
WO WO2020012037
· 2020
[cited by examiner]
WO WO2020014591A1
· 2020
[cited by applicant]
WO WO2020037215A1
· 2020
[cited by applicant]
WO WO2020043835A1
· 2020
[cited by applicant]
WO WO2020079427A1
· 2020
[cited by applicant]
Martinez-Sobrido et al. (Journal of Virology. 2006; 80 (3): 1130-1139).
[cited by examiner]
SEQ ID No. 6 alignment with Geneseq db access No. AEH30839 Apr. 2006.
[cited by examiner]
SEQ ID No. 3 alignment with Genesdeq db access No. AAZ44617 Apr. 2000.
[cited by examiner]
SEQ ID No. 10 alignment with Genesdeq db access BBN47024 Nov. 2014.
[cited by examiner]
SEQ ID No. 9 alignment with GenEmbl db access AF295543 2001.
[cited by examiner]
SEQ ID No. 1 alignment with Geneseq db access AEH30838 2006.
[cited by examiner]
SEQ ID No. 17 UniPtot db acc No. Q8B9N8_9MONO 2003.
[cited by examiner]
SEQ ID No. 16 alignment with GenEmbl db access AY145301 2003.
[cited by examiner]
SEQ ID No. 20 alignment with GenEmbl db access AY845400 2005.
[cited by examiner]
McGinnes et al. (Journal of Virology. 2011; 366-377).
[cited by examiner]
Kim et al. (Viruses. 2016; 8 (7): 183).
[cited by examiner]
Instant SEQ 21 alignment with Geneseq db access ARL59598 by Bu et al. in CN1869234-2008.
[cited by examiner]
Abolnik et al., 2012, “Full genomic sequence of an African avian paramyxovirus type 4 strain isolated from a wild duck,” Virus Genes, 45(3):537-541.
[cited by applicant]
Afonso et al., 2016, “Taxonomy of the order Mononegavirales: update 2016,” Arch Virol., 161(8):2351-2360.
[cited by applicant]
Aigner et al., “An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins,” Int. J. Oncol., 32(4): 777-789 (2008).
[cited by applicant]
Akhras et al., 2010, “Human metapneumovirus and respiratory syncytial virus: subtle differences but comparable severity,” Infect. Dis. Rep., 2(2):e12 (5 pages).
[cited by applicant]
Alexander et al., 1978, “Relationship of parakeet/Netherlands/449/75 virus to other avian paramyxoviruses,” Res. Vet. Sci., 25(1):105-106.
[cited by applicant]
Alexander et al., 1981, “Characterization of viruses from doves representing a new serotype of avian paramyxoviruses,” Arch. Virol., 68(3-4):265-269.
[cited by applicant]
Alexander, “Newcastle disease, Newcastle disease virus—an avian paramyxovirus,” Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 1-22 (1988).
[cited by applicant]
Al-Lazikani et al., “Standard conformations for the canonical structures of immunoglobulins,” J. Mol. Biol., 273(4):927-948 (1997).
[cited by applicant]
Alper et al., 2009, “Rate of concurrent otitis media in upper respiratory tract infections with specific viruses,” Arch. Otolaryngol. Head Neck Surg., 135(1):17-21.
[cited by applicant]
Altomonte et al., “Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma,” Mol. Ther., 18: 275-284 (2010).
[cited by applicant]
Andral et al., 1984, “Isolation of avian paramyxovirus 2 and 3 from turkeys in Brittany,” Vet. Rec., 114(23):570-571.
[cited by applicant]
Annels et al., “Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus,” Mol. Ther. Oncolytics, 9:1-12 (2018).
[cited by applicant]
Assudani et al., “Immunotherapeutic potential of DISC-HSV and OX40L in cancer,” Cancer Immunol. Immunother., 55:104-111 (2006).
[cited by applicant]
Ayers et al., “IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade,” J. Clin. Invest., 127(8):2930-2940 (2017).
[cited by applicant]
Ayllon et al., 2013, “Rescue of Recombinant Newcastle Disease Virus from cDNA,” J. Vis. Exp., (80):e50830.
[cited by applicant]
Baca et al., “Antibody humanization using monovalent phage display,” J. Biol. Chem., 272(16):10678-10684 (1997).
[cited by applicant]
Bai et al., 2002, “Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients,” Int. J. Oncol., 21(4):685-694.
[cited by applicant]
Bankowski et al., 1981, “Effect of paramyxovirus yucaipa on fertility, hatchability, and poult yield of turkeys,” Avian. Dis., 25(2):517-520.
[cited by applicant]
Barber et al. “Restoring function in exhausted CD8 T cells during chronic viral infection,” Nature 439:682-687, with Supplemental Material attached (2006).
[cited by applicant]
Bart et al., “Role of interferon in the anti-melanoma effects of poly (I).poly (C) and Newcastle disease virus,” Nat. New. Biol., 245:229-230 (1973).
[cited by applicant]
Bauzon et al., 2014, “Armed therapeutic viruses—a disruptive therapy on the horizon of cancer immunotherapy,” Front. Immunol., 5(74):1-10.
[cited by applicant]
Blackburn et al., “Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion,” J. Virol., 84(4):2078-2089 (2010) (Epub Dec. 2, 2009).
[cited by applicant]
Blake et al., “Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution,” Anal. Biochem., 272(2):123-134 (1999).
[cited by applicant]
Bohle et al., 1990, “Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avi…
[cited by applicant]
Bohnsack et al., “Adaptation of the Immune-Related Response Criteria: irRECIST,” ESMO, Abstract 4958, pp. 1-8 (2014).
[cited by applicant]
Boisseau, 1993, “Basis for the evaluation of the microbiological risks due to veterinary drug residues in food,” Vet. Microbiol., 35(3-4):187-192.
[cited by applicant]
Brahmer et al., “Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates,” J. Clin. Oncol., 28(19):3167-3175 (…
[cited by applicant]
Brahmer et al., “Safety and activity of anti-PD-L1 antibody in patients with advanced cancer,” N. Engl. J. Med., 366(26):2455-2465 (2012).
[cited by applicant]
Briand et al., 2012, “Complete genome sequence of a novel avian paramyxovirus,” J Virol., 86(14):7710.
[cited by applicant]
Brinkmann et al., “Phage display of disulfide-stabilized Fv fragments,” J. Immunol. Methods, 182(1):41-50 (1995).
[cited by applicant]
Brown et al., “Role of PD-1 in regulating acute infections,” Curr. Opin. Immunol., 22(3):397-401 (2010).
[cited by applicant]
Bryant et al., “Development of intermediate-grade (mantle cell) and low-grade (small lymphocytic and marginal zone) human non-Hodgkin's lymphomas xenotransplanted in severe combined immunodeficiency mouse models,” Lab. …
[cited by applicant]
Buchman et al., 2002, “Nasal and otologic effects of experimental respiratory syncytial virus infection in adults,” Am. J. Otolaryngol., 23(2):70-75.
[cited by applicant]
Buijs et al., “Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma,” Viruses, 7:2980-2998 (2015).
[cited by applicant]
Burton et al., “Human antibodies from combinatorial libraries,” Adv. Immunol., 57:191-280 (1994).
[cited by applicant]
Calain et al., “The Rule of Six, a Basic Feature for Efficient Replication of Sendai Virus Defective Interfering RNA,” J. Virol., 67(8):4822-4830 (1993).
[cited by applicant]
Caldas et al., “Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen,” Protein Eng., 13(5):353-360 (2000).
[cited by applicant]
Capua et al., 2004, “Isolation of an avian paramyxovirus type 9 from migratory waterfowl in Italy,” Vet. Rec., 155(5):156.
[cited by applicant]
Car et al., “The Toxicology of Interleukin-12: A Review,” Toxicol. Pathol., 27(1):58-63 (1999).
[cited by applicant]
Carnero et al., 2009, “Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses,” J Virol., 83(2):584-597 (Epub Nov. 12, 2008).
[cited by applicant]
Carpenter et al., “Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells,” J. Immunol., 165(11):6205-6213 (2000).
[cited by applicant]
Carthon et al., “Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial,” Clin. Canc. Res., 16(10):2861-2871 (2010).
[cited by applicant]
Caruso et al., “Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma,” Proc. Natl. Acad. Sci. USA, 93:11302-11306 (1996).
[cited by applicant]
Cassel et al., 1965, “Newcastle Disease Virus as an Antineoplastic Agent,” Cancer, 18:863-868.
[cited by applicant]
Chaiwatpongsakorn et al., 2011, “Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer,” J. Virol., 85(8):3968-3977.
[cited by applicant]
Chen et al., “CD4 T Cells Require ICOS-Mediated P13K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy,” Cancer Immunol. Res., 2(2):167-176 (2013).
[cited by applicant]
Cheng et al., “Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.” J. Virol., 90(1):5343-5352 (2016).
[cited by applicant]
Cho et al., 2018, “Co-expression of the Hemagglutinin and Neuraminidase by Heterologous Newcastle Disease Virus Vectors Protected Chickens against H5 Clade 2.3.4.4 HPAI Viruses,” Sci. Rep., 8(1):16854 (9 pages).
[cited by applicant]
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins,” J. Mol. Biol., 196(4):901-917 (1987).
[cited by applicant]
Chothia et al., “Conformations of immunoglobulin hypervariable regions,” Nature, 342:877-883 (1989).
[cited by applicant]
Chothia et al., “Structural repertoire of the human VH segments,” J. Mol. Biol., 227(3):799-817 (1992).
[cited by applicant]
Chumakov et al., “Oncolytic Enteroviruses,” Mol. Biol. (Mosk), 46(5):639-650 (2012).
[cited by applicant]
Clinical Trial NCT01295827, “Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/Keynote-001) (Keyno…
[cited by applicant]
Cloud et al., 1980, “Characterization of Nine Avian Paramyxoviruses,” Avian Dis., 24(1):139-152.
[cited by applicant]
Colbère-Garapin et al., “A new dominant hybrid selective marker for higher eukaryotic cells,” J. Mol. Biol., 150(1):1-14 (1981).
[cited by applicant]
Copeland et al., 2005, “Functional chimeras of human immunodeficiency virus type 1 Gp120 and influenza A virus (H3) hemagglutinin,” J Virol., 79(10):6459-6471.
[cited by applicant]
Crouse et al., “Expression and amplification of engineered mouse dihydrofolate reductase minigenes,” Mol. Cell Biol., 3(2):257-266 (1983).
[cited by applicant]
Crowe, 2001, “Respiratory syncytial virus vaccine development,” Vaccine, 20 Suppl 1:S32-S37.
[cited by applicant]
Csatary et al., “MTH-68/H oncolytic viral treatment in human high-grade gliomas,” J. Neurooncol., 67:83-93 (2004).
[cited by applicant]